The European Medicines Agency (EMA) is currently reviewing a number of cases of serious brain inflammation (encephalitis and meningoencephalitis) in people taking Zinbryta.
Biogen and AbbVie, the companies which developed and market the drug, have announced that they are withdrawing Zinbryta worldwide.
The EMA advises that:
- anyone currently taking Zinbryta should not stop without first talking to their neurologist or MS nurse
- doctors should review anyone currently taking Zinbryta and discuss switching to an alternative treatment as soon as possible
- no one should begin taking Zinbryta
- anyone who has questions should talk to their neurologist or MS nurse
The company has also informed the EMA that it will stop ongoing clinical studies with Zinbryta in the EU. People in clinical studies who have any question should contact the doctor treating them in their study.
**Update – 7th March 2018**
Following their review, the European Medicines Agency has recommended the immediate suspension and recall of the multiple sclerosis medicine Zinbryta. Further information is available from the Health Products Regulatory Authority